Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026
Beta Bionics (Nasdaq: BBNX) plans to pre-release topline fourth quarter 2025 financial results in the week of January 5, 2026.
Rhea-AI Summary
Beta Bionics (Nasdaq: BBNX) plans to pre-release topline fourth quarter 2025 financial results in the week of January 5, 2026. The pre-release is expected to include net sales, new patient starts, and the percentage of new patient starts reimbursed through the pharmacy benefit plan (PBP). Company management will hold in-person investor meetings in San Francisco from January 12–14, 2026 to discuss the topline results. Investors may register for meetings by contacting investor relations at ir@betabionics.com.
Positive
- None.
Negative
- None.
Details
News Market Reaction – BBNX
On Dec 8, the day this news came out, BBNX closed 3.64% below the previous close.
Data tracked by StockTitan Argus for the Dec 8 session.
Key Figures
- Q4 2025 period
- Fourth quarter 2025
- Quarter for upcoming topline financial pre-release
- Pre-release week
- Week of January 5, 2026
- Expected timing for topline Q4 2025 pre-announcement
- Investor meetings window
- January 12–14, 2026
- In-person meetings in San Francisco to discuss Q4 2025 topline results
Historical Context
-
Announcement of November and December 2025 healthcare conference presentations.
-
Strong Q3 growth, higher margins, and raised full‑year 2025 revenue guidance.
-
Scheduling of Q3 2025 results release and earnings call details.
-
Planned participation in three major healthcare investor conferences in Sept 2025.
-
Strong Q2 growth, higher gross margin, and raised full‑year 2025 revenue guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pharmacy benefit plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to pre-release its topline fourth quarter 2025 financial results the week of January 5, 2026.
Topline financial results covered in the pre-release are expected to include net sales, new patient starts, and the percentage of new patient starts reimbursed through the pharmacy benefit plan (PBP) channel.
Members of the Company’s management team will host in-person meetings in San Francisco from January 12, 2026 through January 14, 2026 to discuss topline fourth quarter 2025 results. The Company invites investors to register for in-person meetings by contacting the Company’s investor relations representative at ir@betabionics.com.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Karen Hynes
Vice President of Marketing
media@betabionics.com
Source: Beta Bionics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.